Earnings Releases·Nov 12, 2026, 7:05 AM ET

EyePoint — Third Quarter 2026 Earnings Summary

Revenue declined to $0.8 million for Q3 2026 from $1.0 million in the prior year period, while operating expenses rose to $97.6 million from $63.0 million, resulting in a net loss of $95.6 million compared to $59.7 million in 2025.
Cash and investments decreased to $118 million as of September 30, 2026, from $306 million at year-end 2025; management projects current liquidity, combined with a subsequent $10 million equity raise, will fund operations into late Q3 2027.
The company executed a strategic shift to conclude the Phase 3 wet AMD program to prioritize the DME pipeline, where Phase 2 VERONA met its primary endpoint and Phase 3 COMO and CAPRI trials are fully enrolled with data expected in early Q4 2027.
The Board approved a 53% workforce reduction and operational adjustments expected to yield approximately $30 million in annualized savings, while a Nasdaq compliance risk and an FDA warning letter regarding the Watertown manufacturing facility remain key challenges.